Nature of the Business |
12 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| Nature of the Business | 1. Nature of the Business Enanta Pharmaceuticals, Inc. (collectively with its subsidiary, the “Company”), incorporated in Delaware in 1995, is a biotechnology company that uses its robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs with an emphasis on viral infections and immunological diseases. The Company discovered glecaprevir, the second of two antiviral protease inhibitors discovered and developed through its collaboration with AbbVie, Inc. ("AbbVie") for the treatment of acute or chronic infection with hepatitis C virus, or HCV. Glecaprevir is co-formulated as part of AbbVie’s leading brand of direct-acting antiviral combination treatment for HCV, which has been marketed under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir) since 2017 for the treatment of chronic HCV. MAVYRET®/MAVIRET® were also approved as the first and only treatments for acute HCV infection in the United States and the European Union in June 2025 and June 2026, respectively, as well as several other countries including Canada and Australia. The Company is subject to many of the risks common to companies in the biotechnology industry, including but not limited to, the uncertainties of research and development, competition from technological innovations of others, dependence on collaborative arrangements, protection of proprietary technology, dependence on key personnel and compliance with government regulation. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approvals, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure, and extensive compliance reporting capabilities. Liquidity In October 2025, the Company closed an underwritten public offering of its common stock. The Company issued and sold 7,475 shares of its common stock at a public offering price of $10.00 per share. The aggregate net proceeds of the offering were $69,948, after deducting underwriting discounts and commissions and other offering expenses. In July 2026, the Company entered into an Open Market Sale AgreementSM with Jefferies LLC ("Jefferies"), as sales agent, under which the Company may offer and sell shares of its common stock, from time to time through Jefferies, under an at-the-market facility for aggregate gross sale proceeds of up to $75.0 million (the "ATM Facility"). As of September 30, 2026, the Company has not issued any shares of common stock under the ATM Facility. |